Prostate Cancer Clinical Trial
Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia
Summary
The purpose of this project is to evaluate the safety, efficacy, and feasibility of performing prostatic artery embolization (PAE) using endovascular techniques and particle embolics in men suffering from lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).
Full Description
This pilot study is a prospective, non-randomized clinical trial assessing the safety and feasibility of prostatic artery embolization. Fifty adult male subjects will be enrolled and treated in this study. Patients who provide informed consent and are deemed eligible for participation will undergo prostatic artery embolization in the Interventional Radiology department at the University of Virginia. After performing an angiogram to identify the prostatic arteries, tiny particles known as Embozene Microspheres will be injected into the prostatic artery. Injecting these particles into the prostatic artery will slow blood flow to the prostate and thus shrinking the size of the prostate. By shrinking the size of the prostate, it is hopeful that it will provide relief of lower urinary tract symptoms due to BPH. Subjects will be followed for 2 years as part of their participation in this study.
Eligibility Criteria
Inclusion Criteria:
Patients between ages 45-80 years
Diagnosis of Lower Urinary Tract Symptoms from Benign Prostatic Hypertrophy for a minimum of 6 months
IPSS score at initial evaluation should be greater than 7, and uroflowmetry (Qmax) of <12mL/s (milliliters per second) .
All prostate volumes will be at least 40gm and no more than 400gm based on DRE, TRUS, or cross sectional imaging
Exclusion Criteria:
Patients with urinary tract infections (> 2/year), prostatitis, or interstitial cystitis
Cases of biopsy proven prostate cancer or urethral cancer.
Patients on long-term narcotic analgesia, androgen therapy, or GNRH (gonadotropin-releasing hormone) analogue therapy within 2 months of study.
Patients who are classified as New York Heart Association Class III (Moderate), or higher.
Patients with history of prior pelvic irradiation.
Hypersensitivity reactions to contrast material not manageable with prophylaxis.
Patients with serum creatinine values >1.7mg/dl or glomerular filtration rates less than 50.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Charlottesville Virginia, 22908, United States More Info
Principal Investigator
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.